Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT02168101Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2014
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Sep 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02168101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168101.